EXPLORE!

Trial to test safety of investigational vaccine for respiratory syncytial virus begins

  1090 Views

eMediNexus    18 June 2018

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched Phase 1 trial of an investigational vaccine designed to protect against respiratory syncytial virus (RSV). The trial will enroll a small group of healthy adult volunteers to examine the safety of an experimental intranasal vaccine and its ability to induce an immune response. The study is being conducted at the Cincinnati Children’s Hospital Medical Center, one of the NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs).

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.